Milrinone Tillomed

Milrinone, the active ingredient in Milrinone Tillomed, is a phosphodiesterase‑3 (PDE3) inhibitor presented as an intravenous solution for intravenous use. It provides inotropic support and vasodilation, and is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients requiring rapid hemodynamic improvement.

GNH USA supplies Milrinone Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, ensuring quality‑assured product availability across regulated markets.

Milrinone is a phosphodiesterase‑3 inhibitor used in acute cardiac conditions to improve heart contractility and reduce vascular resistance. - Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid inotropic support to stabilize blood pressure. - Post‑cardiac surgery low‑output syndrome: enhances myocardial performance during peri‑operative care.

Milrinone may be associated with a range of adverse reactions, which are categorized by frequency and clinical severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure.

Serious or Rare Side Effects: - Severe ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm, or shock.

Milrinone requires careful monitoring and specific safety measures before and during therapy. - Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Dose adjustment: reduce or discontinue in patients with severe renal impairment. - Electrolyte balance: correct hypokalemia and hypomagnesemia before initiation. - Concomitant vasodilators: use cautiously with other agents that lower blood pressure. - Pregnancy and lactation: avoid unless benefits outweigh potential risks; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, requiring avoidance or close monitoring.

Major Interactions (Avoid): - Concurrent use with other phosphodiesterase inhibitors: may cause excessive vasodilation and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma concentrations, raising toxicity risk. - High-dose beta‑adrenergic agonists: additive inotropic effect may precipitate arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances, increasing arrhythmia risk. - Anticoagulants: monitor for bleeding if thrombocytopenia develops. - Nitrates: combined vasodilatory effect may enhance hypotension.